Get started

Stocktrading

Does Solana will continue their bounce play more than 45% !!Solana has gained more than 45 % from last fall down that was in 5th August 2024 the trend right now is inside the range ( Phase C - Wyckoff Method ) The far target is 216 ( Top of the side way range) if the Re-accumulation phase has succeed. SL is 141.46 ( this for me is consider thin stop loss due to the high BINANCE:SOLUSDT volatility of the crypto market) I am Just sharing insights and market trends for learning and growing every day and it is not financial advice.
Long
by FSelim55
4
TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment. Why Wall Street's bullish in this drug company ? First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity. However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders. Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases. For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients. Teva Pharmaceutical's financial performance and 2024 outlook After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million. Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents. What factors contribute to Teva Pharmaceutical's success? To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments. We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter. First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market. In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter. What factors led to the recovery of Teva's generics business? The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio. The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow. Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea. I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia. However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million. Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event. Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars. For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy. However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX). Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase. However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China. The question arises: "Are there any positives?" The short answer is yes. Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter. What is driving this sales growth? Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices. Now lets talk about Risks Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis. In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance. With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits. To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance. The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market. So TEVA Pharmaceutical is a BUY? YUP
NYSE:TEVALong
by moonypto
Teva Pharmaceuticals (TEVA) Analysis Company Overview: Teva Pharmaceuticals, a global leader in generics and specialty medicines, is poised for growth as it expands its biosimilar portfolio and resolves major legal challenges. Key Catalysts: Biosimilar Launch: NYSE:TEVA plans to launch AVT04, a biosimilar to Johnson & Johnson's blockbuster drug Stelara, by February 2025. Stelara, which generates $10 billion in annual sales, presents a significant market opportunity for Teva as a lower-cost alternative. This biosimilar could drive substantial revenue growth for the company. Opioid Settlement: The resolution of the $4.3 billion opioid settlement reduces legal uncertainty and allows Teva to focus on business expansion. This development provides a clearer path forward for the company’s financial health. Operational Improvements: With improved supply chains and enhanced gross margins, Teva is positioned to strengthen profitability. This operational efficiency will be crucial in boosting the company's bottom line as it rolls out new products. Investment Outlook: Bullish Outlook: We are bullish on TEVA if it holds above the $15.50-$16.00 range. Upside Potential: The upside target for Teva Pharmaceuticals is set at $23.00-$24.00, driven by the upcoming biosimilar launch, legal clarity, and improved operational performance. 💊 Teva Pharmaceuticals—biosimilar potential and legal resolution set to unlock growth! #TEVA #Pharma 🚀📈
NYSE:TEVALong
by Richtv_official
Nvidia Stock Soars On Blowout GuidanceSoaring demand for the chips needed to train the latest wave of generative artificial intelligence systems such as ChatGPT led Nvidia to issue a revenue forecast far ahead of Wall Street expectations, prompting a surge in its stock price in after market trading. The US chipmaker on Wednesday said it expected sales to reach 11bn dollar in the three months to the end of July, more than 50 per cent ahead of the 7.2bn dollar analysts had been expecting and confirming its position as the biggest short-term beneficiary of the AI race that has broken out in the technology industry. The forecast fuelled a 27 per cent leap in Nvidia’s shares, which had already more than doubled since the start of the year, and lifted its stock market value to a record 960 bn dollar. Jensen Huang, chief executive, said the company was “significantly increasing our supply to meet surging demand” for its entire family of data centre chips, including the H100, a product launched this year that was designed to handle the demands of so-called large language models such as OpenAI’s GPT4. The race in the tech industry to develop larger AI models has led some customers to worry privately about a shortage of H100 chips, which only went on sale earlier this year. However, Nvidia’s $4.28bn in sales to data centre customers in its latest quarter topped even the most optimistic analysts’ forecasts, and the company said there had been strong sales of both the H100 and its A100 chips, based on its previous chip architecture. Nvidia’s forecast noted a potential doubling of sales to data centre customers in three months, even though data centre sales were running at an annualised rate of $17bn in the opening quarter of this year. Growth is coming from customers across the board, Kress said, with consumer internet companies, cloud computing providers and enterprise customers all rushing to apply the generative AI to their businesses. The bullish forecast came as Nvidia reported revenue and earnings in its latest quarter, to the end of April, had also topped forecasts, thanks to a jump in sales to data centre customers as demand for AI took off. Revenue reached $7.19bn, up 19 per cent from the preceding three months but down 13 per cent from the year before, as sales of chips for gaming systems dropped. Earnings per share rose 22 per cent from a year before to 82 cents, or $1.09 on the pro forma basis Wall Street judges the company. The consensus view on Wall Street had been for revenue of $6.52bn and pro forma earnings of 92 cents a share. now let's delve into the numbers. Nvidia's different business units did not all perform equally well during the quarter - which can be expected, of course. Nvidia's data center business grossed revenues of $4.3 billion during the first quarter, which represents a new record high. Data center demand is not very cyclical, and companies kept investing in new equipment despite a potential recession being on the horizon. This can be explained by the fact that data centers are mission critical for many companies, so they don't really have a lot of choice when it comes to allocating capital to this space. Strong data center sales also have been seen in the results of other chip companies such as Advanced Micro Devices (AMD). Both Nvidia and AMD also were able to benefit from the weak performance of their competitor Intel (INTC), as Intel has been losing market share in the data center space in recent quarters due to self-inflicted problems and an unconvincing product line-up. Nvidia is a major graphic chip or GPU player and is thus heavily impacted by the performance of related end markets. This includes both cryptocurrency mining and gaming. While some cryptocurrencies can't be mined with GPUs economically, such as Bitcoin, others, such as Ethereum, can be mined with GPUs. Ethereum moved from a proof-of-work model to a proof-of-stake model in the fall of 2022, but some miners still use GPUs for Ethereum mining. Not surprisingly, Nvidia's sales to this end market depend on the price for cryptocurrencies - when cryptocurrencies are expensive, miners are more eager to acquire additional GPUs and they may also be willing to pay high prices for them. During times when cryptocurrencies are less expensive, mining is less profitable, and GPU demand from cryptocurrency miners wanes. This has had an impact on Nvidia's sales in the past and likely played a role in Nvidia's Q1 sales as well. GPU sales have been under pressure in recent quarters due to lower demand by gamers as well. Many that like to play video games upgraded their hardware during the lockdown phase of the pandemic when staying at home meant that consumers had more time for video games. With many gamers having relatively new equipment, demand has declined in the recent past. At the same time, inflation pressures consumers' ability to spend on discretionary goods. On top of that, some consumers prefer to spend their money on experiences over things now as there are no lockdowns or travel restrictions in place any longer. All in all, this has resulted in a difficult macro environment for Nvidia's gaming business. Combined, the headwinds for the gaming market and the cryptocurrency market explain why Nvidia's sales and profits kept declining during the most recent quarter, relative to the results the company was able to generate one year earlier. The strong performance in the data center space was not enough to offset the headwinds Nvidia experienced in other areas. I personally going to take huge profit right now and wait for 250 $ levels
NASDAQ:NVDA
by moonypto
5
Coal India bullish swing expectedCoal India is a potential stock which can breakout & can give a good move. Its trading at its resistance on daily time frame. If breaks resistance then min expectation will be 600. its a under valued stock having a P.E 8.97 so can be preffered for long term investment also. Disclaimer: Any of my posts should not be considered as a Buy/ Sell/Hold recommendation. This analysis is for educational and learning purpose only. I always recommend using Stop Loss and following risk management rules.
NSE:COALINDIA
by jain_abhishek
1
SWING IDEA - PETRONET LNGThis presents an attractive opportunity for swing traders to capitalize on the potential uptrend in Petronet LNG . Reasons are listed below : Breakout of Strong Resistance at 300 : Petronet LNG has successfully broken above a significant resistance level at 300, signaling potential bullish momentum. Bullish Marubozu Candle on Weekly Timeframe : The presence of a bullish Marubozu candlestick pattern on the weekly timeframe suggests strong buying momentum and potential upward movement. Breakout from 6+ Years of Consolidation : The stock has broken out from a consolidation phase lasting over 6 years, indicating a significant shift in market sentiment and potential for sustained upward movement. Trading Above 50 and 200 EMA : Petronet LNG is trading above both the 50 and 200 Exponential Moving Averages (EMA), confirming bullish bias and indicating potential for trend continuation. Support from 0.382 Fibonacci Level : Finding support at the 0.382 Fibonacci level and bouncing back reinforces the bullish outlook and provides a solid foundation for potential upward movement. Trading at All-Time High (ATH) : Petronet LNG is trading at its all-time high, indicating strong bullish momentum and potential for further gains. Constant Higher Highs : The stock consistently forms higher highs, reflecting increasing bullish momentum and reinforcing the potential for further gains. Target - 340 // 380 Stoploss - weekly close below 260 DISCLAIMER - Decisions to buy, sell, hold or trade in securities, commodities and other investments involve risk and are best made based on the advice of qualified financial professionals. Any trading in securities or other investments involves a risk of substantial losses. The practice of "Day Trading" involves particularly high risks and can cause you to lose substantial sums of money. Before undertaking any trading program, you should consult a qualified financial professional. Please consider carefully whether such trading is suitable for you in light of your financial condition and ability to bear financial risks. Under no circumstances shall we be liable for any loss or damage you or anyone else incurs as a result of any trading or investment activity that you or anyone else engages in based on any information or material you receive through TradingView or our services. @visionary.growth.insights
NSE:PETRONETLong
by Visionary_Growth_Insights
10
Morepen Laboratories Trading IdeaIntroduction Morepen Laboratories Ltd. engages in the business of manufacturing bulk drugs, intermediates, and medical devices; and business of formulation. It operates through the following geographical segments: the United States of America, Rest of World, and India. Observation Stock Trade all the Ema making rounding bottom after a rejection from 72 level in 2021. now it is trying to breakout the same level once it breakout and sustain above 72 level no one can stop this stock to reach my levels which is 120. on weekly chart you'll see a gap up open marubozu candlestick stock look strong on all the TF. Get the inside scoop! Read the rest of the article on our blog 👆
NSE:MOREPENLABLong
by SHEHBAZ_KHAN
2
CarGurus (CARG) AnalysisCompany Overview: CarGurus, a leading online platform for buying and selling cars, continues to attract investor confidence with its growing user base and strong market positioning. The platform's ability to connect consumers with dealers is driving its popularity, making it a significant player in the automotive marketplace. Key Highlights: Rising User Engagement: CarGurus saw a 3% increase in average monthly users, a strong indicator of consumer engagement and platform relevance. This growth reflects the company's effectiveness in attracting and retaining users, crucial for long-term success. Analyst Optimism: Analysts are bullish on CarGurus' prospects. JPMorgan Chase & Co. raised their target price to $32.00, while BTIG Research set theirs at $30.00, both maintaining a "Buy" rating. This analyst confidence highlights the market's positive view of CarGurus' growth trajectory. Revenue Growth: The company's Marketplace business reported its largest quarterly revenue increase since 2021. This growth was driven by higher adoption of add-on products, a shift to premium service tiers, and expansion of its global dealer base, all contributing to stronger financial performance. Investment Outlook: Bullish Outlook: We are bullish on NASDAQ:CARG above the $23.00-$24.00 range. Upside Potential: With an upside target of $35.00-$36.00, CarGurus presents a compelling growth opportunity as it continues to enhance its platform, expand its dealer network, and increase user engagement. 📈🚗 CarGurus—driving growth and accelerating your portfolio! #CARG #Automotive 🚗💼
NASDAQ:CARGLong
by Richtv_official
TSLA / TESLATSLA (Tesla, Inc.) Stock Analysis: Key Dates and Potential Market Movements: 1. August 23, 2024 - Potential Upside: • Scenario: The chart indicates a potential bullish movement around late August 2024. This could be driven by positive earnings reports, advancements in Tesla’s technology, or an increase in market optimism around Tesla’s leadership in the EV market. • Impact on Price: We might see a short-term rally in Tesla’s stock price, pushing it towards previous highs around the $270 mark. 2. October 15, 2024 - Potential Downside: • Scenario: As we approach mid-October 2024, the chart suggests a potential bearish phase. This could be due to broader market corrections, profit-taking by investors, or any negative news related to supply chain disruptions or increased competition in the EV market. • Impact on Price: Tesla’s stock could see a pullback, potentially testing support levels around $215 or even lower. 3. February 19, 2025 - Recovery Phase: • Scenario: By early 2025, the chart indicates a recovery phase, possibly due to strong Q4 2024 earnings, the introduction of new Tesla models, or significant advancements in battery technology. • Impact on Price: This period might mark the beginning of a new bullish trend, with Tesla’s stock price climbing back towards the $250-$300 range. 4. May 9, 2025 - Consolidation or Continued Growth: • Scenario: The market could enter a consolidation phase, where the stock trades within a range, or Tesla could continue its growth trajectory depending on the broader economic conditions and Tesla’s performance. • Impact on Price: If the market conditions are favorable, Tesla might break out to new highs; otherwise, we could see sideways movement in the $250-$300 range. 5. September 4, 2025 - Potential Market Shift: • Scenario: As we approach late 2025, the chart suggests another critical phase, potentially influenced by macroeconomic factors, such as changes in interest rates or shifts in consumer demand for EVs. • Impact on Price: This could lead to either a breakout to new highs or a retest of lower support levels, depending on the prevailing market sentiment. 6. December 4, 2025 - Year-End Rally: • Scenario: The end of 2025 could see a year-end rally, driven by strong sales numbers, holiday season demand, or favorable policy decisions regarding EV subsidies. • Impact on Price: Tesla’s stock might experience a strong rally, potentially setting new highs or revisiting levels around $300. Considerations for Investors: • Technological Advancements: Tesla’s continued innovation in battery technology, autonomous driving, and energy solutions could be key drivers of its stock price. • Market Sentiment: Investor sentiment around the EV market and broader technology sector will play a crucial role in Tesla’s stock movements. • Geopolitical and Economic Factors: Changes in global trade policies, supply chain disruptions, and shifts in consumer demand could impact Tesla’s performance. Given the potential market shifts and Tesla’s leadership in the EV space, are you considering adding Tesla to your portfolio? How do you see Tesla’s position evolving as we approach key market dates in 2024 and 2025?
NASDAQ:TSLA
by trushkovskiy
I AM BULLISH ON AAPL STOCK. BUY AT $218.5In the recent market activity, APPLE (AAPL) stock experienced a significant decline, dropping to approximately $196 on the 5th of this month. This event marked a challenging day for both the financial markets and the cryptocurrency sector. Currently, AAPL has rebounded to $221. Based on my analysis, I see an opportunity to enter the market at the $219 level, with a short-term target set at $224. To manage risk, a stop loss (SL) is strategically placed at $218.5. Despite the recent volatility, AAPL continues to present strong potential for investors.
NASDAQ:AAPLLong
by ForexClinik
Tyson Foods (TSN) Analysis Company Overview: Tyson Foods, a global leader in meat production and distribution, is well-positioned to benefit as the economy shows signs of slowing. In times of economic uncertainty, investors often turn to consumer staples like Tyson Foods as a defensive play due to their steady demand and generous dividends. Key Highlights: Economic Hedge: As fears of a hard landing grow, Tyson Foods stands out as a safe investment option. The company's products remain in demand even during economic downturns, making it a reliable choice for risk-averse investors. Insider Confidence: Significant insider activity, including stock accumulation by Congress members in 2024, signals strong confidence in the company's future performance. Insiders with an informational edge are betting on Tyson’s continued success. Dividend Growth: Tyson Foods' CEO recently announced an increase in the company’s quarterly dividend, with the 2024 dividend expected to be 2% higher than in 2023. This dividend boost reflects the board's confidence in the company’s financial health and growth prospects. Investment Outlook: Bullish Outlook: We are bullish on NYSE:TSN above the $54.00-$55.00 range. Upside Potential: With an upside target of $85.00-$86.00, Tyson Foods offers a combination of defensive stability, income generation through dividends, and potential for capital appreciation, making it an attractive investment in uncertain economic times. 📈🍗 Tyson Foods—feeding your portfolio with dividends and growth potential! #TSN #Dividends 🍗💼
NYSE:TSNLong
by Richtv_official
AMZN / AMAZON 🔍 AMZN Analysis: Strategic Dates for Long-Term Accumulation 📈 The AMZN chart reveals key dates that could shape your investment strategy: December 29, 2025 & August 16, 2027 - Green Lines: These dates indicate potential local lows, making them ideal for accumulating AMZN shares. Investors should consider these as prime opportunities to position themselves for the next major upward trend in the stock. By planning around these dates, you can optimize your long-term investment strategy and take advantage of potential market corrections. #AMZN #StockMarket #InvestmentStrategy #NASDAQ #SNP500 #MarketTiming #Amazon
NASDAQ:AMZN
by trushkovskiy
AME potential Buy setupReasons for bullish bias: - Price at a strong support level - Price retraced from 0.786 fib level and it broke the 0.5 resistance level as well - Strong bullish weekly closing at a rising trendline - Bullish divergence Here are the recommended trading levels: Entry Level(CMP): 163.28 Stop Loss Level: 135.60 Take Profit Level 1: 185.24 Take Profit Level 2: Open Note: An SL at 145.58 can also be placed as it's a strong support zone but the trend structure will only break if 135.60 breaks, partial profit at 175.88 can also be taken.
NYSE:AMELong
by TradeWithParas
1
NIKE | JUST BUY ITNike topped Wall Street estimates for first quarter profit on Thursday as higher prices of its sneakers and apparel helped offset a hit from waning demand and persistent cost pressures, sending its shares up about 8% in extended trading. Nike (NKE) is the largest apparel company in the world, with leading positions across different categories and regions. The company is currently facing challenges such as elevated inventory levels, inflationary pressure, and slow growth in China. Such issues have resulted in the stock dropping by 19% YTD. Although these headwinds are serious, I believe the company's durable brand, leading position, and high-quality products should allow it to come out stronger on the other end. 'Nike is a brand that is of China and for China' -John Donahoe Like every other apparel and retail company, Nike thought post-pandemic demand would continue, so it increased production, which led to inventory levels hitting an all-time high in Q1-FY22, but as we know, that wasn't the case. Although NKE's inventory level is down from all-time highs, investors are still concerned, especially when inflation is eating into people's pockets and growth in China is slowing. Inflation in North America has come down to 3.7% from its peak in June at 9.1%, but it is still a concern in Europe (6.1% in the EU union). As you can see from the graph below, sales in China have been decreasing for the past two years. There are multiple ways one can explain this: COVID related lockdowns resulted in the shuttering of some stores. Plus, Nike and other apparel companies started facing a backlash in China in 2021 due to the alleged use of forced labor in cotton production. However, if the company is successful at expanding into China, then we can expect a lot of room for growth. Now that I have addressed the problems that are facing Nike, let me explain why I believe the company will overcome them. Nike sponsors the most well-known athletes such as Cristiano Ronaldo (+600 million Instagram followers), LeBron James, Michael Jordan, the late Kobe Bryant, Rafael Nadal, Tiger Woods, and more. This has helped the company build a loyal customer base and further boost its brand equity. With a loyal customer base comes pricing power, and as Warrant Buffet said: Nike's pricing power is no joke. Its shoes have reached a level where they are considered luxury, with some selling for more than the $10,000 mark. In 2017, Nike's median price for a shoe regardless of gender was $80, which is $10 more than its biggest competitor, Adidas. I know 2017 was a long time ago, but shoe prices have increased since then, and I believe Nike is still in the lead given their dominant market position. Plus, Nike targets mostly the age demographic of 25 and 34. These are people who have not settled in yet. They just graduated college with extra income to spend on things such as expensive shoes. I believe this pricing power will continue as the company continues to sponsor talented upcoming athletes to build trust with customers. Another way to measure Nike's brand power is by comparing its marketing spending against its peers. Nike's marketing budget in FY 23 was $4 billion, or 7.9% of revenue. On the other hand, Adidas spent 38% and Under Armour 11%. These companies have been allocating more of their revenue towards marketing but have experienced nowhere near the growth Nike has. NKE's association with well-known athletes in the U.S. has allowed them to have a 96% awareness rate, 53% usage rate, and 43% loyalty rate. Going forward, I expect the company's brand will remain high-quality due to sponsorships, high-quality products, and market-leading technology. Founded by Bill Bowerman and Phil Knight in 1994, Nike has come a long way from its first store in Portland, Oregon. As of May 31, 2023, the company had 369 stores within the U.S. and 663 internationally, operating in more than 190 countries. Stores include franchised stores and third-party retailers. The firm owns multiple brands such as Jordan, Converse, and Nike. The company derives sales from four main segments and across four regions. I excluded Converse (4.74% of revenue) from the graphs below because I wanted to focus on the Nike brand. The company's app, NikePlus, has more than 160 million users. On a trailing free cash flow basis, the stock yields over 3.3% relative to its enterprise value. My ~$104 May 24 PT implies a 28.00x P/E and 20.00x EV/EBITDA. Both multiples are below the ten-year NTM average and in line with the median. I project revenue to compound at a rate of 6.47% over the next three years, driven by market growth and new products, while shares decrease at a rate of 2.67%, driven by stock buybacks. The company is forecast to spend $12.1 billion on share repurchases over the same period. Additionally, I believe the company still has room for margin improvement driven by price increases and DTC mix (direct-to-consumer). In FY 2019, DTC sales constituted 31% of revenue, and that figure stood at 44% in FY 2023. Although NKE is trading at a premium compared to peers, I believe it is reasonable considering its scale, high-quality products, and strong brand. The first risk that I would associate with NKE is competition. The company competes with conglomerates such as Addidas, Puma, New Balance, Under Armour, and more. Additionally, e-commerce has made it very easy for anyone to start their own footwear brand. Other key risks to my rating include supply chain distributions, a recessionary environment, and slow growth in China. Finally, we can point out that NKE appears technically oversold heading into the Q1 earnings report. From the chart , there has been relentless selling pressure over the last four months since NKE was trading at $130 per share. The potential that NKE delivers a "good" earnings report with encouraging guidance, brushing aside fears the company is facing a deeper deterioration in its operating environment could be enough for shares to reprice higher. Simply put, our take is that NKE bears have gone too far, opening the door for bulls to take control. The bottom line is that Nike is currently experiencing headwinds such as elevated inventory levels, inflationary pressure, and slow growth in China. Every business goes through similar challenges at one time or another, but I believe Nike is well-positioned to overcome these issues due to its durable brand, high-quality products, and leading position. I expect the company to keep endorsing high-quality athletes to elevate its brand equity and further strengthen its pricing power. My valuation implies a price target of ~$104 for May 31, 2024. If you into NIKE brand you can watch Air film and read Shoe Dog book as well
NYSE:NKELong
by moonypto
20
AAPL / APPLE🔍 AAPL Analysis: Key Dates for Market Movements 📈 The AAPL chart highlights two critical dates that could shape your trading strategy: October 7, 2024 - Red Line: This date marks a potential local peak. It might be an opportune moment to take profits as the stock could face resistance or enter a short-term correction. August 25, 2025 - Green Line: A significant local low is expected around this time. This could present an ideal opportunity to accumulate AAPL shares, positioning yourself for the next major upward move. By strategically planning around these dates, you can optimize your trading decisions and maximize returns. #AAPL #StockMarket #MarketTiming #InvestmentStrategy #AppleStock
NASDAQ:AAPLShort
by trushkovskiy
A Guide on How to Stay on the Right Side of Market RiskStaying on the right side of the market is the only thing that matters in investing. The goal is simple: be long the things that go up and avoid the things that go down. Although this sounds straightforward, investors often focus too much on the upside potential and forget about the downside. In reality, avoiding the downside is by far the most important factor that will have the biggest impact on your total returns. This is because a -50% loss will always require a +100% gain just to break even. Step 1: Follow the Trend The most effective method to stay on the right side of the market is by following the trend, primarily through moving averages. The two most common types are the Simple Moving Average (SMA) and the Exponential Moving Average (EMA). The EMA assigns more weight to recent price movements, making it more responsive and effective for signalling the start of a downtrend, while the SMA offers a clearer view of the longer-term trend. The simplest way to construct a trend-following indicator is to combine a short-term EMA with a long-term EMA. A buying signal is triggered when the short-term EMA crosses above the long-term EMA, and a selling signal is triggered when it crosses below. This systematic approach ensures clear and actionable signals. Optimizing this strategy involves backtesting various EMA combinations to strike a balance between minimal trading frequency, lowest maximum drawdown, and highest profit factor. It’s also crucial to select assets that have historically adhered to trends, as these are more likely to continue doing so. Assets that typically adhere to trends, such as cryptocurrencies, fiat currencies, commodities, and tech stocks, are often driven by speculative or uncertain future expectations. By incorporating a longer-term SMA and adding a safety margin to the calculation, you can help minimize false signals from the EMAs. It’s advisable to compare asset performance not only against the USD pair but also against the safest investable asset in the selected asset class. This comparison helps determine if the additional risk is worth taking. Step 2: Draw the Lines Trend-following strategies are effective only with a clear market trend. Without it, prices may exhibit range-bound movements and generate false signals. Drawing trend lines and identifying horizontal support and resistance levels are crucial for enhancing the accuracy of these signals. The most reliable entry points typically follow a confirmed breakout from these lines, with older lines often indicating more significant breakouts. When drawing trend lines, it’s crucial to use both normal and logarithmic chart scales. The most reliable trend lines appear consistent across these scales, with a breakout observed on both further confirming the trend. Additionally, identifying reliable patterns like head and shoulders, inverse head and shoulders or double tops and bottoms can further validate trend breakouts. TradingView’s pattern recognition tools can automate this process and provide price targets, which can be helpful but are not always guaranteed. Step 3: Understand the Macro Following current macroeconomic conditions can enhance your understanding of the overall business cycle. The primary macro forces that influence asset markets are growth, inflation, and policy. These factors are subjective and not directly quantifiable, making them unsuitable for direct investment decisions. However, they are useful for assessing the market’s risk appetite, which should influence only your position size and not your systematic approach. The US Composite Leading Indicator (CLI) is one of the most informative macroeconomic indicators, providing insights into potential economic growth trends and helping anticipate inflections in the business cycle. Monitoring the US inflation and unemployment rates is also beneficial, as they significantly influence monetary policy. While minor fluctuations may not provide much insight, sustained trends that align with the Federal Reserve’s targets of 2% inflation and low unemployment are indicative of a healthy economy. Furthermore, tracking global liquidity can reveal the real-time effects of monetary and fiscal policies implemented by major central banks and governments. This serves as a valuable tool to assess the market’s risk appetite. In conclusion, this guide helps investors stay on the right side of the market by adopting a systematic approach that captures bull markets while avoiding major downturns. Recognizing that the future is unpredictable and that markets are driven by momentum, this method can both preserve and grow your wealth in a less stressful way. A disciplined, systematic approach, executed dispassionately, is essential for navigating market uncertainties. All indicators discussed are publicly available or can be accessed on my profile. Disclaimer: This article is for informational and educational purposes only and should not be construed as investment advice.
NASDAQ:NVDAEducation
by ingeforberg
5
Life Time Group (LTH) AnalysisCompany Overview: Life Time Group operates health and wellness clubs across the U.S. and Canada. Recently, the company completed a $40 million sale-leaseback transaction, which CEO Bahram Akradi views as a strategic move to strengthen the balance sheet and drive future growth. Key Highlights: Strategic Financial Moves: The $40 million sale-leaseback transaction aims to improve financial flexibility and support expansion efforts. Positive Cash Flow: Akradi projects that Life Time will achieve positive cash flow by Q2, even after accounting for capital expenditures. Debt Reduction: The company plans to reduce its net debt leverage ratio to 2.0 by year-end, which could positively impact its stock price. Insider Confidence: CEO Bahram Akradi purchased $654,000 worth of stock at $16.76, contributing to a total of $3.2 million in insider purchases over the past year, signaling strong confidence in the company's future. Investment Outlook: Bullish Outlook: We are bullish on NYSE:LTH above the $20.00-$21.00 range. Upside Potential: With an upside target of $35.00-$36.00, investors should consider Life Time Group's strategic financial moves, expected positive cash flow, and insider confidence as key factors for potential stock appreciation. 📈💪 Keep an eye on Life Time Group for a healthy investment opportunity! #LTH #WellnessClubs 🏋️‍♂️🚀
NYSE:LTHLong
by Richtv_official